The results showed that treatment with a single dose (5 mg/kg) of BETd-260 for 24 h significantly suppressed the expression of BRD2, BRD3 and BRD4 in tumor tissue of both HCC models (Figures 5A,B). Here, BRD3 is linked to hepatocellular carcinoma.